Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan vs Esomeprazole in GERD
NCT07326904Phase 3Completed
- Sponsor
- Universitas Indonesia
- Start
- Aug 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fexuprazan in gastroesophageal reflux disease (GERD), sponsored by Universitas Indonesia. Started Aug 2024; status: completed.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07326904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326904.